Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (AMPH) Revenue
Annual & quarterly revenue history · segment & region breakdown
AMPH · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAmphastar Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.72B, a decrease of 1.65% year-over-year from $0.72B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.72B | -$0.01B | -1.65% |
| 2024-12-31 | $0.73B | +$0.09B | +13.59% |
| 2023-12-31 | $0.64B | +$0.15B | +29.14% |
| 2022-12-31 | $0.50B | +$0.06B | +13.98% |
| 2021-12-31 | $0.44B | +$0.09B | +25.13% |
| 2020-12-31 | $0.35B | +$0.03B | +8.53% |
| 2019-12-31 | $0.32B | +$0.03B | +9.40% |
| 2018-12-31 | $0.29B | +$0.05B | +22.69% |
| 2017-12-31 | $0.24B | -$0.01B | -5.87% |
| 2016-12-31 | $0.26B | +$0.00B | +1.45% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare AMPH revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Amphastar Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Amphastar Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Amphastar Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AMPH revenue · 5 questionsAMPH's trailing twelve-month (TTM) revenue is $0.72B. That is a decrease of 1.65% year-over-year from $0.72B in FY2025.
▸ Source: FMP · Amphastar Pharmaceuticals, Inc. SEC filings · GAAP · Amphastar Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026